|
[1] Hoare M, Levy M S, Bracewell D G, et al. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic. Biotechnol Prog, 2005, 21(6):1577-1592.
[2] Urthaler J, Buchinger W, Necina R. Improved downstream process for the production of plasmid DNA for gene therapy. Act Biochim Polonica, 2005, 52(3): 703 -711.
[3] Cai Y, Rodriguez S, Hebel H. DNA vaccine manufacture: scale and quality. Expert Rev Vaccines, 2009, 8(9): 1277-1291.
[4] Luo D, Saltzman W M. Synthetic DNA delivery systems. Nat Biotechnol, 2000, 18: 33-37.
[5] 朱玉贤, 李毅. 现代分子生物学. 第2版.北京: 高等教育出版社, 2002. 172-179. Zhu Y X, Li Y. Modern Molecular Biology. 2nd ed. Beijing: Higher Education Press, 2002. 172-179.
[6] Yau S Y, Keshavarz-Moore E, Ward J. Host strain influences on supercoiled plasmid DNA production in Escherichia coli: Implications for efficient design of large-scale processes. Biotechnol Bioeng, 2008, 101(3): 529-544.
[7] Schleef M, Blaesen M. Production of plasmid DNA as a pharmaceutical methods in molecular biology. Gene Therapy of Cancer, 2009, 542: 471-495.
[8] Zhang Q L, Bi J J, Xiao F J, et al. Production of plasmid DNA encoding human hepatocyte growth factor for gene therapy, Biotech Appl Biochem, 2008, 49(1): 11-16.
[9] Chen Z Y, He C Y, Meuse L, et al. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther, 2004, 11(10): 856-864.
[10] Chen Z Y, He C Y, Ehrhardt A, et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular Therapy, 2003, 8(3):495-500.
[11] Mayrhofer P, Blaesen M, Schleef M, et al. Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med, 2008, 10: 1253-1269.
[12] Carnes A E, Luke J M, Vincent J M, et al. Plasmid DNA fermentation strain and process-specific effects on vector yield, quality and transgene expression. n/a. doi: 10.1002/bit.22936.
[13] Carnes A E. Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Int, 2005, 36-44.
[14] Tejeda-Mansir A, Mmontesinos R. Upstream processing of plasmid DNA for vaccine and gene therapy applications. Recent Patents on Biotechnology, 2008, 2: 156-172.
[15] Mairhofera J, Cserjan-Puschmanna M, Striednera G, et al. Marker-free plasmids for gene therapeutic applications-Lack of antibiotic resistance gene substantially improves the manufacturing process. J Biotechnol, 2010, 146: 130-137.
[16] Schorr J, Moritz P, Breul A, et al. Production of plasmid DNA in industrial quantities according to cGMP guidelines. Methods Mol Med, 2006, 127: 339-350.
[17] Meacle F J, Lander R, Ayazi S P, et al. Impact of engineering flow conditions on plasmid DNA yield and purity in chemical cell lysis operations. Biotechnol Bioeng, 2004, 87(3): 293-302.
[18] Hebel H, Attra H, Khan A, et al. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine, 2006, 24(21): 4607-4614.
[19] Li X L, Jin H L, Wu Z F, et al. A continuous process to extract plasmid DNA based on alkaline lysis. Nat Protocols, 2008, 3(2): 176-180.
[20] Urthaler J, Ascher C, Wohrer H, et al. Automated alkaline lysis for industrial scale cGMP production of pharmaceutical grade plasmid-DNA. J of Biotechn, 2007, 128: 132-149.
[21] Theodossiou I, Conllins I J, Ward J M, et al. The processing of a plasmid-based gene from E.coli. primary recovery by filtration. Bioprocess Eng, 1997, 16:175-183.
[22] Eon-Duval A, Gumbs K, Ellett C. precipitation of RNA impurities with high salt in a plasmid DNA purification process: use of experimental design to determine reaction conditions. Biotechnol Bioeng, 2003, 83(5): 544-553.
[23] Monteiro G A, Ferreira G N M, Cabral J M S, et al. Analysis and use of endonuclease activities in Escherichia coli lysates during the primary isolation of plasmids for gene therapy. Biotechnol Bioeng. 1999, 66: 189-194.
[24] Frerix A, Geilenkirchen P, Muller M, et al. Separation of genomic DNA, RNA, and open circular plasmid DNA from supercoiled plasmid DNA by combining denaturation, selective renaturation and aqueous two-phase extraction. Biotechnol Bioeng, 2007, 96(1): 57-66.
[25] German P G, Prazeres D M F, Guzman R, et al. Purification of plasmid DNA using tangential flow filtration and tandem anion-exchange membrane chromatography. Bioprocess Biosyst Eng, 2009, 32: 615-623.
[26] 邵英光, 李京华, 魏桂林, 等. 内毒素的去除策略. 广州化学, 2003, 28(2): 38-45. Shao Y G, Li J H, Wei G H, et al. Guangzhou Chemistry, 2003, 28(2): 38-45.
[27] 蔡慧丽. 生物技术药品分离纯化过程中内毒素的去除. 海峡药学, 2006, 18(2): 157-159. Cai H L. Strait Pharmaceutical Journal, 2006, 18(2): 157-159.
[28] Rezaee A, Ghanizadeh G, Behzadiyannejad G, et al. Adsorption of endotoxin from aqueous solution using bone char. Bull Environ Contam Toxicol, 2009, 82: 732-737.
|
